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Follicular lymphoma (FL) continues to pose a clinical chal-
lenge with a progressive disease course typified by multiple
relapses, eventual resistance to standard therapies and
transformation (tFL) in a subset of patients to the more
aggressive diffuse large B cell lymphoma (DLBCL).
WGS was performed on 6 paired FL-tFL patients and
corresponding germ-lines to understand the clonal
dynamics of progression and recurring genetic events in
FL. We identified that the dominant pattern of FL evolu-
tion to transformation was consistent with the existence of
a common origin, an ancestral common progenitor cell
(CPC) population. Strikingly, the CPCs were enriched for
mutations in chromatin regulatory genes with every case
harbouring mutations in MLL2, a histone methyltransfer-
ase, concurrent with mutations in other methyltransferases
(EZH2, MLL3, PRMT2), acetyltransferases (CREBBP,
MEF2B), bromodomain proteins (BRD2, CECR2), core
and linker histones. Targeted deep sequencing of EZH2
showed mutations in 27% of cases in an extension cohort
of 366 cases, much higher than previously reported. All
mutations targeted the catalytic SET domain leading to a
gain-of-function thus offering the possibility of using
EZH2 inhibitors.
The plethora of genetic mutations in epigenetic regula-
tors in FL shown in this study therefore offers a compelling
model disease to strategically test epigenetically-targeted
therapies.
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